Inovio reports Q1 EPS (28c), consensus (33c)

Estimates current cash, cash equivalents and short-term investments balances sufficient into 1Q27, beyond the target PDUFA date for INO-3107. Reports Q1 revenue $0, consensus $250K. “We remain focused on advancing INO-3107 toward its target PDUFA date to ensure that every RRP patient has access to therapeutic options that work for them to reduce the need for surgery. We believe there remains a critical unmet need among patients diagnosed with this rare and devastating disease, and that INO-3107 has the potential to become the preferred product by patients and their physicians, if approved, based on clinical results, tolerability data and the simplicity of its patient-centric treatment regimen that does not require additional surgeries during the dosing window,” said CEO Jacqueline Shea. “While the BLA for INO-3107 is under active review, we continue to advance our commercial readiness plans in anticipation of a 2026 approval, as well as leverage the power of partnerships to advance other promising candidates in our pipeline.”